MOACM
BEAM icon

Mutual of America Capital Management’s Beam Therapeutics BEAM Stock Holding History

Mutual of America Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-26,531
Closed -$812K – 1469
2023
Q1 		$812K Sell
26,531
-1,222
-4% -$48.2K 0.01% 1056
2022
Q4 		$1.09M Buy
27,753
+6,248
+29% +$280K 0.01% 1025
2022
Q3 		$1.02M Buy
+21,505
New +$1.23M 0.01% 1023

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mutual of America Capital Management's BEAM Position: Q2 2023 in Review

Mutual of America Capital Management sold out of Beam Therapeutics (BEAM) in Q2 2023, closing a stake of 26,531 shares — an estimated $812K sold.

Mutual of America Capital Management first reported a position in BEAM in Q3 2022 and held it in 3 quarters. The position peaked at $1.09M in Q4 2022. 194 funds tracked by Wall St. Rank hold BEAM as of Q2 2023.

  • Mutual of America Capital Management reported no remaining Beam Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Mutual of America Capital Management sold 26,531 Beam Therapeutics shares in Q2 2023, an estimated $812K.
  • Mutual of America Capital Management first reported a position in Beam Therapeutics in Q3 2022 and held it in 3 quarters.
  • Mutual of America Capital Management's Beam Therapeutics position peaked at $1.09M in Q4 2022.
  • 194 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2023.

Based on Mutual of America Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.